Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC2 | O15270 | 6/20 | 0.48 |
| ▸ | TACR1 | P25103 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 3/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4150202 | 0.93 | SPTLC2 (0.45) | SPTLC2TACR1EPHX2F2RCCR2 | |
| SCHEMBL4150200 | 0.93 | SPTLC2 (0.45) | SPTLC2TACR1EPHX2F2RCCR2 | |
| SCHEMBL4141820 | 0.92 | KCNH2 (0.46) | TACR1 | |
| SCHEMBL4141816 | 0.92 | KCNH2 (0.46) | TACR1 | |
| SCHEMBL4163877 | 0.91 | RHOC (0.49) | SPTLC2F2RCCR2 | |
| SCHEMBL4162645 | 0.91 | SPTLC2 (0.41) | SPTLC2TACR1F2RCCR2 | |
| SCHEMBL4154345 | 0.91 | TACR1 (0.44) | SPTLC2TACR1F2RCCR2 | |
| SCHEMBL4163875 | 0.91 | RHOC (0.49) | SPTLC2F2RCCR2 | |
| SCHEMBL4154346 | 0.91 | TACR1 (0.44) | SPTLC2TACR1F2RCCR2 | |
| SCHEMBL4162644 | 0.91 | SPTLC2 (0.41) | SPTLC2TACR1F2RCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | SPTLC2 3640/4885TACR1 9/4885EPHX2 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.